AU2020346456A1 - TAK-925 for use in treating narcolepsy - Google Patents
TAK-925 for use in treating narcolepsy Download PDFInfo
- Publication number
- AU2020346456A1 AU2020346456A1 AU2020346456A AU2020346456A AU2020346456A1 AU 2020346456 A1 AU2020346456 A1 AU 2020346456A1 AU 2020346456 A AU2020346456 A AU 2020346456A AU 2020346456 A AU2020346456 A AU 2020346456A AU 2020346456 A1 AU2020346456 A1 AU 2020346456A1
- Authority
- AU
- Australia
- Prior art keywords
- compound
- subject
- methyl
- administration
- plasma concentration
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962900298P | 2019-09-13 | 2019-09-13 | |
| US62/900,298 | 2019-09-13 | ||
| US202063031686P | 2020-05-29 | 2020-05-29 | |
| US63/031,686 | 2020-05-29 | ||
| PCT/IB2020/058483 WO2021048822A1 (en) | 2019-09-13 | 2020-09-12 | Tak-925 for use in treating narcolepsy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2020346456A1 true AU2020346456A1 (en) | 2022-04-14 |
Family
ID=72560858
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2020346456A Abandoned AU2020346456A1 (en) | 2019-09-13 | 2020-09-12 | TAK-925 for use in treating narcolepsy |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20220339143A1 (https=) |
| EP (1) | EP4028004A1 (https=) |
| JP (1) | JP2022547711A (https=) |
| KR (1) | KR20220062012A (https=) |
| CN (1) | CN114980892A (https=) |
| AU (1) | AU2020346456A1 (https=) |
| BR (1) | BR112022004587A2 (https=) |
| CA (1) | CA3154321A1 (https=) |
| CO (1) | CO2022004596A2 (https=) |
| MX (1) | MX2022003018A (https=) |
| WO (1) | WO2021048822A1 (https=) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20220062361A (ko) * | 2019-09-13 | 2022-05-16 | 다케다 야쿠힌 고교 가부시키가이샤 | 과도한 졸림의 치료를 위한 오렉신 2 수용체 효능제의 용도 |
| AU2021205892B2 (en) | 2020-01-10 | 2026-04-23 | Takeda Pharmaceutical Company Limited | A method for enhancing the pharmacokinetics or increasing the plasma concentration of methyl 3-((methylsulfonyl)amino)-2-(((4-phenylcyclohexyl)oxy)methyl)piperidine-1-carboxylate or a salt thereof with an inhibitor of cytochrome P450 |
| CN116583502A (zh) | 2020-09-03 | 2023-08-11 | 欧瑞夏治疗有限公司 | 二环-杂环衍生物及其作为食欲素-2受体激动剂的用途 |
| US20240165092A1 (en) * | 2021-04-02 | 2024-05-23 | Takeda Pharmaceutical Limited Company | Use of an orexin 2 receptor agonist for post operation recovery |
| IL316468A (en) | 2022-04-22 | 2024-12-01 | Teijin Pharma Ltd | The aftermath of oxazepine |
| WO2024075825A1 (ja) | 2022-10-07 | 2024-04-11 | キッセイ薬品工業株式会社 | シクロペンタン化合物 |
| EP4611745A1 (en) * | 2022-10-31 | 2025-09-10 | Takeda Pharmaceutical Company Limited | Dosing of orexin type 2 receptor agonists |
| TW202535890A (zh) | 2023-10-20 | 2025-09-16 | 日商帝人製藥股份有限公司 | 氧氮呯衍生物之結晶或其溶劑合物之結晶 |
| WO2025124698A1 (en) | 2023-12-12 | 2025-06-19 | Idorsia Pharmaceuticals Ltd | Aryl sulfone and sulfanone derivatives as orexin receptor modulators |
| TW202542165A (zh) | 2023-12-19 | 2025-11-01 | 瑞士商愛杜西亞製藥有限公司 | 大環食慾素激動劑 |
| WO2025229493A1 (en) * | 2024-04-29 | 2025-11-06 | Takeda Pharmaceutical Company Limited | Dosing of orexin type 2 receptor agonists |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0815134B1 (en) | 1995-03-14 | 2002-06-05 | Praecis Pharmaceuticals Incorporated | Modulators of amyloid aggregation |
| PT929574E (pt) | 1996-08-27 | 2005-11-30 | Praecis Pharm Inc | Moduladores da agregacao de peptidos beta-amiloides compreendendo d-aminoacidos |
| EP1196609A2 (en) | 1999-06-28 | 2002-04-17 | Oklahoma Medical Research Foundation | Catalytically active recombinant memapsin and methods of use thereof |
| MX376164B (es) * | 2014-10-23 | 2025-03-07 | Eisai R&D Man Co Ltd | Composiciones y metodos para tratar el insomnio. |
| WO2016201373A1 (en) * | 2015-06-12 | 2016-12-15 | Axovant Sciences Ltd. | Diaryl and arylheteroaryl urea derivatives useful for the prophylaxis and treatment of rem sleep behavior disorder |
| LT3984994T (lt) * | 2016-02-04 | 2024-10-10 | Takeda Pharmaceutical Company Limited | Pakeistas piperidino junginys kaip 2 tipo oreksino agonistas narkolepsijai gydyti |
-
2020
- 2020-09-12 AU AU2020346456A patent/AU2020346456A1/en not_active Abandoned
- 2020-09-12 BR BR112022004587A patent/BR112022004587A2/pt unknown
- 2020-09-12 WO PCT/IB2020/058483 patent/WO2021048822A1/en not_active Ceased
- 2020-09-12 EP EP20775077.9A patent/EP4028004A1/en not_active Withdrawn
- 2020-09-12 US US17/642,331 patent/US20220339143A1/en not_active Abandoned
- 2020-09-12 CN CN202080073637.7A patent/CN114980892A/zh active Pending
- 2020-09-12 CA CA3154321A patent/CA3154321A1/en active Pending
- 2020-09-12 JP JP2022516270A patent/JP2022547711A/ja active Pending
- 2020-09-12 MX MX2022003018A patent/MX2022003018A/es unknown
- 2020-09-12 KR KR1020227011013A patent/KR20220062012A/ko active Pending
-
2022
- 2022-04-11 CO CONC2022/0004596A patent/CO2022004596A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA3154321A1 (en) | 2021-03-18 |
| JP2022547711A (ja) | 2022-11-15 |
| EP4028004A1 (en) | 2022-07-20 |
| CN114980892A (zh) | 2022-08-30 |
| KR20220062012A (ko) | 2022-05-13 |
| WO2021048822A1 (en) | 2021-03-18 |
| BR112022004587A2 (pt) | 2022-06-14 |
| US20220339143A1 (en) | 2022-10-27 |
| MX2022003018A (es) | 2022-06-14 |
| CO2022004596A2 (es) | 2022-08-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2020346456A1 (en) | TAK-925 for use in treating narcolepsy | |
| US20220331303A1 (en) | Use of an orexin 2 receptor agonist for the treatment of excessive sleepiness | |
| US12594269B2 (en) | Method for enhancing the pharmacokinetics or increasing the plasma concentration of methyl 3-((methylsulfonyl)amino)-2-(((4-phenylcyclohexyl)oxy)methyl)piperidine-1-carboxylate or a salt thereof with an inhibitor of cytochrome P450 | |
| WO2024095158A1 (en) | Dosing of orexin type 2 receptor agonists | |
| JP2015509931A (ja) | 医薬的な組み合わせ | |
| Napoliello et al. | Buspirone: a worldwide update | |
| JP7607864B2 (ja) | Ｋｖ７チャネル活性化剤の使用方法 | |
| AU2022252108A1 (en) | Use of an orexin 2 receptor agonist for post operation recovery | |
| WO2022190060A1 (en) | An orexin 2 receptor agonist for the treatment of an orexin-mediated disease or disorder | |
| US20090306050A1 (en) | Treatment and prevention of depression with pain, depression secondary to pain, and of neuropathic pain | |
| JP2008514689A (ja) | Ａｄｈｄ、ｃｆｓ、ｆｍおよび鬱病の処置のためのロフェプラミンの薬学的な組成物の使用 | |
| HK40113570A (en) | Methods of use for kv7 channel activators | |
| CA3270681A1 (en) | Dosing of orexin type 2 receptor agonists | |
| JP2010513227A (ja) | 覚醒を促進するためのＩｈチャネル阻害剤 | |
| Kompoliti et al. | Non‐Parkinsonian Movement Disorders | |
| HK40000275B (en) | Compounds having melatonin receptor affinity as prophylactic or therapeutic agent for delirium |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK4 | Application lapsed section 142(2)(d) - no continuation fee paid for the application |